Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody
Authors:
Open Access
- 14 September 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (18) , 5926-5934
Abstract
Purpose: Many solid tumors express cell surface mesothelin making them attractive targets for antibody-based therapies of cancer. SS1P [antimesothelin(Fv)PE38] is a recombinant immunotoxin (RIT) that has potent cytotoxic activity on several cancer cell lines and clinical activity in mesothelioma patients. Pancreatic cancers express mesothelin and are known to be resistant to most chemotherapeutic agents. The goal of this study is to treat pancreatic cancer with RIT by targeting mesothelin. Experimental Design: We measured the cytotoxic activity of an antimesothelin immunotoxin on pancreatic cancer cells. We also measured the levels of several pro- and antiapoptotic proteins, as well as the ability of TNF-related apoptosis-inducing ligand (TRAIL) or the anti-TRAIL receptor 2 agonist antibody (HGS-ETR2) to kill pancreatic cells, and the cytotoxic activity of the two agents together in cell culture and against tumors in mice. Results: In two pancreatic cancer cell lines, immunotoxin treatment inhibited protein synthesis but did not produce significant cell death. The resistant lines had low levels of the proapoptotic protein Bak. Increasing Bak expression enhanced the sensitivity to immunotoxins, whereas Bak knockdown diminished it. We also found that combining immunotoxin with TRAIL or HGS-ETR2 caused synergistic cell death, and together triggered caspase-8 recruitment and activation, Bid cleavage and Bax activation. Combining SS1P with HGS-ETR2 also acted synergistically to decrease tumor burden in a mouse model. Conclusion: Our data show that low Bak can cause cancer cells to be resistant to immunotoxin treatment and that combining immunotoxin with TRAIL or a TRAIL agonist antibody can overcome resistance. Clin Cancer Res; 17(18); 5926–34. ©2011 AACR.Keywords
All Related Versions
This publication has 40 references indexed in Scilit:
- Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC levelCell Death & Differentiation, 2010
- Pancreatic CancerNew England Journal of Medicine, 2010
- Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinomaJournal of Cell Biology, 2010
- Human Caspases: Activation, Specificity, and RegulationJournal of Biological Chemistry, 2009
- Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumorsAnnals of Oncology, 2009
- Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonistProceedings of the National Academy of Sciences, 2008
- Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonist AntibodyJNCI: Journal of the National Cancer Institute, 2008
- Mesothelin targeted cancer immunotherapyEuropean Journal of Cancer, 2008
- Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumorsProceedings of the National Academy of Sciences, 2007
- Immunotoxin therapy of cancerNature Reviews Cancer, 2006